Welcome to LookChem.com Sign In|Join Free
  • or
Cyclopropanesulfonamide, N-(1,1-dimethylethyl)-1-ethyl- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

681808-55-9

Post Buying Request

681808-55-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

681808-55-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 681808-55-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,1,8,0 and 8 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 681808-55:
(8*6)+(7*8)+(6*1)+(5*8)+(4*0)+(3*8)+(2*5)+(1*5)=189
189 % 10 = 9
So 681808-55-9 is a valid CAS Registry Number.

681808-55-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name N-tert-butyl-1-ethylcyclopropane-1-sulfonamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:681808-55-9 SDS

681808-55-9Relevant academic research and scientific papers

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

-

Page/Page column 213, (2009/01/20)

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

-

Page/Page column 40, (2010/02/06)

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 681808-55-9